Receiving two designations, RMAT and Breakthrough Therapy, from independent FDA reviews validates our positive #CARTcells clinical results and urgent need for a treatment for #DIPG. We're moving to initiate the pivotal trial by the end of 2025. #BrainChildTargetsCNSCancer
brainchildbio.com/press/